Eosinophils are bi-lobed granulocytic leukocytes comprising 1-4% of circulating white cells, characterized by large cytoplasmic granules packed with cytotoxic proteins (major basic protein, eosinophil peroxidase, eosinophil cationic protein, eosinophil-derived neurotoxin) designed primarily for anti-helminth defense. They are evolutionary specialists recruited to tissue sites by eotaxin chemokines (CCL11, CCL24, CCL26) binding CCR3, where they degranulate to release both tissue-damaging weapons and resolution mediators, making them paradoxical actors in both defense and pathology.
Think of eosinophils as SWAT teams with grenades designed for one specific threat — parasitic worms — but now patrolling a city that rarely sees that enemy. Each eosinophil carries pre-packaged explosive granules (major basic protein) that can punch holes in a worm's cuticle. The problem: in modern environments, these cells are deployed against pollen, dust mites, and food proteins instead. Imagine calling in heavily armed explosive units to deal with a package delivery — they show up, throw grenades (degranulation), damage the neighborhood (airway epithelium in asthma), then stick around releasing chemical signals (IL-4, IL-13) that call in more SWAT teams. The collateral damage is what we call allergic inflammation. But here's the twist: these same cells also carry repair kits — they produce Lipoxin A4 and other resolution molecules. They're simultaneously arsonists and firefighters, depending on what signals they receive. In the meningeal spaces, they're stationed permanently as border patrol against the original threat (parasites entering via cerebrospinal fluid), showing that the brain never forgot the worm wars even if Western immune systems did.
¶ Development and Recruitment
Eosinophil development occurs in bone marrow under control of IL-5 (primary growth factor), IL-3, and GM-CSF:
- IL-5 → IL-5Rα (CD125) → JAK2/STAT5 activation → transcription of eosinophil lineage genes
- Mature eosinophils released with 8-12 hour blood half-life, 2-5 day tissue survival
- Tissue recruitment via eotaxin (CCL11/CCL24/CCL26) → CCR3 → integrin activation → transendothelial migration
- VCAM-1 and α4β1 integrin mediate adhesion to inflamed endothelium
- Chemoattractants also include C5a, Leukotriene B4, PAF, IL-8
Upon activation, eosinophils execute multiple simultaneous programs:
Degranulation cascade:
- IgE-antigen complexes → FcεRI crosslinking → calcium flux → granule fusion
- Major basic protein (MBP) released — directly cytotoxic to helminths and host epithelium
- Eosinophil peroxidase (EPO) generates reactive oxygen species: H₂O₂ + halide → hypochlorous acid
- Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) — RNase superfamily proteins damaging membranes
Lipid mediator production:
- Phospholipase A2 → arachidonic acid release
- 15-lipoxygenase pathway: arachidonic acid → 15-HETE → lipoxin A4 (pro-resolution)
- 5-lipoxygenase: arachidonic acid → LTB4, LTC4 → bronchoconstriction, vascular permeability
- Platelet-activating factor (PAF) synthesis
Cytokine amplification:
Specialized functions:
- Antigen presentation via MHC-II to T cells
- Mast Cells bidirectional regulation via direct cell contact
- NETosis-like release of DNA traps (EETosis — eosinophil extracellular traps)
graph TB
IL5[IL-5 from Th2/ILC2/Mast Cells] --> IL5R["IL-5Rα on Eosinophil"]
IL5R --> JAK2[JAK2/STAT5]
JAK2 --> Survival["Survival + Proliferation"]
Eotaxin[Eotaxin CCL11] --> CCR3
CCR3 --> Migration[Tissue Migration]
IgE[IgE-Antigen] --> FcER["FcεRI Crosslinking"]
FcER --> Ca["Ca²⁺ Influx"]
Ca --> Degran[Degranulation]
Degran --> MBP[Major Basic Protein]
Degran --> EPO[Eosinophil Peroxidase]
Degran --> ECP[Eosinophil Cationic Protein]
MBP --> Damage[Epithelial Damage]
EPO --> ROS[Reactive Oxygen Species]
ECP --> Neurotox[Neurotoxicity]
AA[Arachidonic Acid] --> LOX15[15-Lipoxygenase]
AA --> LOX5[5-Lipoxygenase]
LOX15 --> LXA4[Lipoxin A4 - Resolution]
LOX5 --> LTC4[LTC4 - Inflammation]
Cytokines[IL-4/IL-13 Production] --> Th2[Th2 Amplification]
Cytokines --> M2[M2 Macrophage Activation]
¶ Apoptosis and Resolution
Eosinophil clearance is tightly regulated:
- Glucocorticoids → glucocorticoid receptor → eosinophil apoptosis (therapeutic target)
- Siglec-8 (sialic acid-binding Ig-like lectin-8) engagement → caspase activation → apoptosis
- IL-5 withdrawal → loss of survival signals → spontaneous apoptosis
- Efferocytosis by macrophages → TGF-beta and IL-10 release → resolution
Eosinophils constitutively present in all three meningeal layers (dura mater, arachnoid, pia mater):
- Anti-parasitic surveillance — helminth larvae can migrate via bloodstream to CNS
- CXCR3 expression allows CNS recruitment
- Proximity to Mast Cells and macrophages enables rapid allergic response at blood-brain interface
- May contribute to migraine pathophysiology via mast cell cross-activation
- Normal count: 100-400 cells/μL (1-4% of total leukocytes)
- Mild eosinophilia: 500-1,500 cells/μL — suggests atopy, early parasitic infection
- Moderate eosinophilia: 1,500-5,000 cells/μL — allergic disease, drug reactions, helminth infections
- Severe eosinophilia: >5,000 cells/μL — hypereosinophilic syndrome, eosinophilic leukemia, Churg-Strauss vasculitis
- Tissue eosinophilia: >20 eosinophils per high-power field in esophagus = eosinophilic esophagitis
Eosinophils represent a Type 1 evolutionary mismatch (Metamodel 0): they evolved as specialized anti-helminth defenses during millions of years when parasitic worm burden was universal. The modern Western absence of helminths (hygiene hypothesis) leaves eosinophils unemployed, leading to:
- Inappropriate deployment against harmless antigens (pollen, food proteins) → Allergy
- Chronic activation without resolution → Asthma, eosinophilic esophagitis
- Loss of regulatory helminths that would normally dampen eosinophil responses via IL-10 and Treg cells
The selfish immune system principle applies: eosinophils prioritize their own survival (via IL-5 autocrine loops) over host welfare, creating self-perpetuating allergic inflammation.
In asthma:
- Eosinophils drive airway remodeling via TGF-β, VEGF, MMP-9 secretion
- Can constitute >50% of bronchoalveolar lavage cells in severe eosinophilic asthma
- Anti-IL-5 therapy (mepolizumab, reslizumab) reduces exacerbations by depleting eosinophils
- Blood eosinophils >300 cells/μL predict better steroid response
In eosinophilic esophagitis:
- Food antigen-driven eosinophil infiltration → dysphagia, esophageal strictures
- Requires >15 eosinophils per high-power field on biopsy
- Responds to elimination diets (remove cow's milk, wheat, egg, soy, nuts, fish) or swallowed Glucocorticoids
In parasitic infections:
- Eosinophils >1,000 cells/μL with travel history → stool ova and parasite testing
- Strongyloides, Ascaris, Toxocara, Schistosoma commonly elevate eosinophils
- Effective killing requires antibody opsonization + eosinophil degranulation
Therapeutic interventions:
- Siglec-8 agonists (lirentelimab) induce selective eosinophil apoptosis without broad immunosuppression
- Anti-IL-5 antibodies (mepolizumab) prevent bone marrow production and tissue recruitment
- Anti-CCR3 antagonists block tissue homing
- High-dose Glucocorticoids induce apoptosis but risk metabolic side effects
- Helminth therapy (Trichuris suis ova) experimental for refractory allergic disease — restores ancestral immune regulation
- Metamodel 1 (Stressors): Chronic psychological stress elevates Cortisol initially suppressing eosinophils, but cortisol resistance develops → paradoxical eosinophilia
- Metamodel 2 (Information Processing): Eosinophils respond to dietary lectins and AGEs as damage signals → chronic low-grade activation
- Metamodel 3 (Bioenergetics): Eosinophils are glycolytic cells requiring glucose; Insulin resistance affects their tissue distribution
- Metamodel 5 (Circadian/Seasonal): Eosinophil counts show circadian variation (peak at night, nadir in morning) opposite to Cortisol
- Normal lifespan: 8-12 hours in circulation, 2-5 days in tissues (extended to weeks in inflamed tissue)
- IL-5 is the master regulator — controls development, activation, survival, and tissue recruitment
- Major basic protein (MBP) has pI >11, making it extremely cationic and membrane-disruptive
- Bi-lobed nucleus distinguishes eosinophils from neutrophils (multi-lobed) and basophils (bi-lobed but larger granules)
- Charcot-Leyden crystals in sputum/stool = crystallized eosinophil lysophospholipase → confirms eosinophilic inflammation
- Present in meningeal spaces at baseline — part of CNS immune surveillance
- 15-lipoxygenase enzyme unique to eosinophils among granulocytes → produces pro-resolution Lipoxin A4
- Eosinophils express FcεRI (IgE receptor), making them direct effectors in IgE-mediated Allergy
- Blood eosinophilia with normal CRP suggests parasitic infection over bacterial infection
- Eosinophil-derived neurotoxin (EDN) is antiviral against RNA viruses — ancestral anti-helminth proteins have secondary antimicrobial functions
- Aspirin-triggered lipoxins (ATL) via COX-2 acetylation shift eosinophils from pro-inflammatory to pro-resolving phenotype
- Hypereosinophilic syndrome (>1,500 eosinophils/μL for >6 months with organ damage) can cause endomyocardial fibrosis — life-threatening
- IL-5 — primary eosinophil growth, survival, and activation factor; therapeutic depletion target
- Allergy — eosinophils are key type 2 inflammation effectors in allergic rhinitis, asthma, atopic dermatitis
- Asthma — eosinophilic airway inflammation drives remodeling and steroid-responsive phenotype
- Th2 — Th2 cells produce IL-5 and IL-4 driving eosinophil recruitment and activation
- Mast Cells — bidirectional cross-talk via direct contact and lipid mediators; synergistic degranulation
- eosinophil apoptosis — regulated by Glucocorticoids, Siglec-8, and IL-5 withdrawal
- Siglec-8 — eosinophil-specific inhibitory receptor; engagement induces selective apoptosis
- Parasitic Infections — eosinophils evolved as primary anti-helminth defense via ADCC and toxic granules
- Cytokines — eosinophils produce IL-4, IL-13, IL-6, TNF-α amplifying type 2 responses
- Meninges — eosinophils constitutively present in all three layers for anti-parasitic CNS surveillance
- Tissue Remodeling — eosinophil-derived TGF-beta, VEGF, MMP-9 drive Fibrosis in chronic inflammation
- Leukocytes — eosinophils are granulocytic subset with specialized anti-parasitic function
- Bone Marrow — eosinophil production site under IL-5, IL-3, GM-CSF control
- CCR3 — chemokine receptor mediating eotaxin-driven tissue recruitment; antagonism prevents homing
- Inflammation — eosinophils contribute to chronic allergic inflammation but also produce resolution mediators
- Glucocorticoids — induce eosinophil apoptosis via mitochondrial pathway; first-line therapy for eosinophilic disorders
- Immune System — eosinophils are innate leukocytes with regulatory, effector, and antigen-presentation functions
- Lipoxin A4 — eosinophil-derived via 15-LOX pathway; pro-resolution lipid mediator
- arachidonic acid — substrate for eosinophil lipid mediator synthesis via lipoxygenase pathways
- IgE — eosinophils express FcεRI and participate in IgE-mediated allergic responses
- hygiene hypothesis — reduced helminth exposure removes regulatory signals dampening eosinophil activation
- Treg cells — produce IL-10 suppressing eosinophil survival and tissue recruitment
- M2 macrophages — activated by eosinophil-derived IL-4/IL-13; collaborate in tissue repair and fibrosis
- NETosis — eosinophils perform EETosis (eosinophil extracellular traps) releasing DNA and granule proteins
- chronic inflammation — persistent eosinophil activation without resolution drives pathological remodeling
- eosinophilic esophagitis — food antigen-driven eosinophil infiltration causing dysphagia and strictures
- Churg-Strauss vasculitis — ANCA-associated vasculitis with severe eosinophilia and asthma